LAVA Therapeutics NV
NASDAQ:LVTX
LAVA Therapeutics NV
NASDAQ:LVTX
Price:
1.27
USD
-1.55%
Market Closed
Market Cap:
33.4m
USD
LAVA Therapeutics NV
Operating Income
|
LAVA Therapeutics NV
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Income
-$43.3m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Income
-$8.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Income
-€30.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-6%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Income
-$177.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-15%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Income
-$14m
|
CAGR 3-Years
66%
|
CAGR 5-Years
41%
|
CAGR 10-Years
-3%
|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Income
-$272.1m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LVTX
Intrinsic Value
1.96
USD
Undervaluation 35%
See Also
What is LAVA Therapeutics NV's Operating Income?
Operating Income
-43.3m
USD
-43.3m
USD
Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Operating Income amounts to -43.3m USD.
What is LAVA Therapeutics NV's Operating Income growth rate?
Operating Income CAGR 3Y
-43%
-43%
Over the last year, the Operating Income growth was -24%. The average annual Operating Income growth rates for LAVA Therapeutics NV have been -43% over the past three years .
You don't have any saved screeners yet